Biogen Idec, Electro-Optical Among “5 Stocks Approaching Greatness”
Investment website The Motley Fool has published a list of five stocks approaching greatness–and four of them are within the life sciences industry.
Profiles
Clarient Stock Deal Frees Up Cash for Safeguard Scientifics
Safeguard Scientifics Inc. has received $19.5 million in cash, and freed up another $12.3 million in cash due to one of its portfolio companies completing the second part of a private placement of convertible preferred stock.
TargetScan Touch Proven Effective in Duke Study
A study published in Technology in Cancer Research and Treatment shows that Envisioneering Medical’s TargetScan Touch system is more effective in detecting prostate cancer than traditional biopsy methods.
TearLab Gets FDA 510(k) Approval
TearLab Corporation has received FDA 510(k) clearance of its TearLab Osmolarity System.
BioNeutral to Expand Into Asia
BioNeutral Group, a developer of chemical-based technology, announced that they will form a new wholly owned subsidiary in Hong Kong to commercialize their proprietary chemical formulations throughout Asia.
Bioject Signs With U.S. Navy for Malaria Vaccine
Bioject Medical Technologies, a developer of needle-free injection systems, has signed a cooperative R&D agreement with the U.S. Navy to use Bioject’s technology in a malaria vaccine the Navy is developing.
Electro-Optical Announces MelaFind Study Results
Electro-Optical Sciences has announced positive results in a clinical trial of the MelaFind System, a handheld imaging device that detects melanomas at an early stage.
Focal Drug Delivery Helps Deadly Brain Tumor, Study Shows
A method of delivering chemotherapy drugs into a deadly type of brain tumor extended the lives of patients in early clinical trials.
Clarient Launches New Breast Cancer Test
Clarient is launching a new breast cancer test that helps physicians assess the probability of a patient’s cancer returning.
Studies Back Gen-Probe’s Prostate Cancer Test
Eight studies presented this week at the American Urological Association Annual Meeting suggest that Gen-Probe’s investigational test for the prostate cancer gene PCA3 may address some of the major challenges faced by urologists when diagnosing the disease.